Vicki Osborne

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 14

Top Topics

Coronavirus Disease

Left Atrial Appendage

Nursing Students

Top Venues

BMJ evidence-based medicine

The American journal of drug and alcohol abuse

Substance use & misuse

This page only lists publications with an associated author ORCID identifier.

Publications

Vicki Osborne, Amie J Goodin, Joshua Brown, Almut G Winterstein, Andrew Bate, Catherine Cohet, Lisa G Pont, David Moeny, Olaf Klungel, Simone Pinheiro, John D Seeger, K Arnold Chan, Stanley Edlavitch, Hugh Tilson, Deborah Layton
Updated core competencies in pharmacoepidemiology to inform contemporary curricula and training for academia, government, and industry. Pharmacoepidemiology and drug safety 33 (4) (2024)
Vicki Osborne, Samantha Lane, Saad A W Shakir
The Role of the Contextual Cohort to Resolve Some Challenges and Limitations of Comparisons in Pharmacoepidemiology. Drug safety 44 (8) (2021)
Vicki Osborne, Miranda Davies, Alison Evans, Saad A W Shakir
Observational assessment of safety in seroquel (OASIS): a specialist cohort event monitoring (SCEM) study in England. Therapeutic advances in psychopharmacology 10 (2020)
Alison Evans, Miranda Davies, Vicki Osborne, Debabrata Roy, Saad Shakir
Incidence of major and clinically relevant non-major bleeding in patients prescribed rivaroxaban for stroke prevention in non-valvular atrial fibrillation in secondary care: Results from the Rivaroxaban Observational Safety Evaluation (ROSE) study. PloS one 15 (10) (2020)
Sandeep Dhanda, Vicki Osborne, Elizabeth Lynn, Saad Shakir
Postmarketing studies: can they provide a safety net for COVID-19 vaccines in the UK? BMJ evidence-based medicine (2020)
Vicki Osborne, Mirsada Serdarevic, Catherine W Striley, Sara Jo Nixon, Almut G Winterstein, Linda B Cottler
Age of First Use of Prescription Opioids and Prescription Opioid Non-Medical Use among Older Adolescents. Substance use & misuse 55 (14) (2020)
Vicki Osborne, Miranda Davies, Debabrata Roy, Francesco Tescione, Saad A W Shakir
Systematic benefit-risk assessment for buprenorphine implant: a semiquantitative method to support risk management. BMJ evidence-based medicine 25 (6) (2020)
Alison Evans, Miranda Davies, Vicki Osborne, Debabrata Roy, Saad Shakir
Evaluation of the incidence of bleeding in patients prescribed rivaroxaban for the treatment and prevention of deep vein thrombosis and pulmonary embolism in UK secondary care: an observational cohort study. BMJ open 10 (11) (2020)
Vicki Osborne, Miranda Davies, Samantha Lane, Alison Evans, Jacqueline Denyer, Sandeep Dhanda, Debabrata Roy, Saad Shakir
Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment. Drug safety 43 (8) (2020)
Vicki Osborne, Catherine W Striley, Sara Jo Nixon, Almut G Winterstein, Linda B Cottler
Sex differences in peer and parental risk factors for non-medical use of prescription opioids in youth. The American journal of drug and alcohol abuse 46 (2) (2019)
Vicki Osborne, Saad A W Shakir
The 9th Biennial Conference on Signal Detection and Interpretation in Pharmacovigilance. Drug safety 41 (1) (2018)
Vicki Osborne, Miranda Davies, Deborah Layton, Saad A W Shakir
Utilisation and Safety of Deferasirox: Results from an Observational Cohort Study in England. Drug safety 41 (3) (2018)
Vicki Osborne, Deborah Layton, Carole Fogg, Edward Tong, Saad A W Shakir
Safety of Atrovent® CFC-free inhaler: respiratory events reported from an observational cohort study in England. The International journal of pharmacy practice 26 (4) (2017)
Vicki Osborne, Mirsada Serdarevic
Potential impact of exposure definition when examining non-medical use of prescription opioids among US veterans. Addiction (Abingdon, England) 112 (8) (2017)